ReviewAccuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: A systematic review
Introduction
Lymph node status, even after neoadjuvant chemotherapy (NAC), is a strong predictor of disease-free and overall survival in breast cancer patients.1, 2, 3 A sentinel node (SN) biopsy is an accurate method to assess nodal status and has now replaced traditional axillary lymph node dissection (ALND) as an initial staging procedure in early-stage, clinically node-negative breast cancer patients.4, 5 Several studies indicated that SN biopsy is also feasible for patients with large primary breast tumours,6, 7, 8 provided there is no clinical nodal involvement.9
NAC, initially introduced to downstage locally advanced breast cancer to facilitate surgery, results in an improved disease-free and overall survival, which is comparable with the effect of adjuvant chemotherapy.10, 11, 12, 13 More recently, the indication for NAC has been extended to selected patients with an earlier stage disease to allow breast-conserving surgery.14, 15 Another potential advantage of a neoadjuvant approach is the opportunity to observe chemosensitivity in situ, providing prognostic information and the ability to identify effective novel therapies.16
Following NAC, nodal staging was traditionally performed by an ALND at the time of breast surgery, which is associated with substantial morbidity.17, 18 Therefore, a less aggressive approach to the axilla is desirable. In fact, this raises not only the question whether these patients could be staged by SN biopsy, but also the question of what the optimal timing is for this procedure with respect to the NAC.
Performing an SN biopsy before NAC, on the one hand, assures accurate assessment of initial nodal status, avoiding the possible negative effects of lymphatic scarring or uneven nodal tumour response. On the other hand, performing SN biopsy after NAC could be an attractive strategy as NAC may downstage nodal status in a number of patients (20–40%).14, 19 Before such a strategy can be recommended as a routine procedure, validation of the safety and predictive value of SN biopsy following NAC is required.
Numerous, generally retrospective, small and single-institution studies assessed the feasibility of SN biopsy after NAC, with varying conclusions. This systematic review was conducted to give an overview of these studies and provide recommendations regarding the role of SN biopsy following NAC.
Section snippets
Literature search strategy
The electronic databases of Medline, Embase and Cochrane were searched from 1993 to February 2009 using free text and controlled terms for breast cancer, SN and NAC. The year 1993 was selected because this was the year of the first publication on the SN. Articles published in English, German, French or Dutch were considered. Two reviewers (C.H.M. van Deurzen and B.E.P.J. Vriens) independently evaluated titles and abstracts of the identified papers. Potentially relevant articles were retrieved
Results
The initial electronic search identified 574 potentially relevant articles of which we screened the title and abstract. After screening, the full texts of 66 articles were obtained. After full-text review and exclusion of overlapping series, 27 articles that met the inclusion criteria of this review remained for data extraction, including single- (N = 23) and multicentre (N = 4) series. The total study population comprised 2148 patients. The main characteristics and results of these studies are
Discussion
This systematic review was conducted to give an overview of the current literature regarding the accuracy of an SN biopsy in breast cancer patients following NAC. We calculated a pooled SN identification rate and false-negative rate of 90.9% and 10.5%, respectively. These rates do not differ substantially from prior multicentre studies evaluating SN success rates without NAC, reporting an identification rate of 88–97% and a false-negative rate of 5–10%.50, 51, 52, 53, 54, 55 However, these
Conflict of interest statement
None declared.
References (58)
- et al.
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer
Am J Surg
(1998) - et al.
Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
Lancet
(1997) - et al.
The binomial distribution of meta-analysis was preferred to model within-study variability
J Clin Epidemiol
(2008) - et al.
Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer
Am J Surg
(2001) - et al.
Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. A pilot study
Eur J Surg Oncol
(2003) - et al.
Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation
J Am Coll Surg
(2004) - et al.
A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important
Am J Surg
(2005) - et al.
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
Lancet Oncol
(2007) - et al.
Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity
Ann Oncol
(2000) - et al.
Meta-analysis of sentinel lymph node biopsy in breast cancer
J Surg Res
(1999)
Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy
Breast Cancer Res Treat
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes
J Clin Oncol
The sentinel node in breast cancer – a multicenter validation study
N Engl J Med
Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors
Cancer
Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer
Ann Surg Oncol
Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers
Am Surg
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer
J Clin Oncol
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
J Clin Oncol
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902
J Clin Oncol
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis
J Natl Cancer Inst
Neoadjuvant chemotherapy for operable breast cancer
Br J Surg
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
J Clin Oncol
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
J Natl Cancer Inst
Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer
J Clin Oncol
Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer
Ann Surg Oncol
Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma
Cancer
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy
Ann Surg
Quantitative methods in the review of epidemiologic literature
Epidemiol Rev
Epidemiology. An Introduction
Cited by (182)
The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer
2024, European Journal of Surgical OncologyMultidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy
2022, Current Problems in SurgeryDoes ‘fast – track’ axillary node clearance following positive core biopsy lead to overtreatment of axilla?
2021, SurgeonCitation Excerpt :Comparable Identification rate and false – negative rate (FNR) is achieved if dual agent technique is used and at least 2–3 nodes are evaluated. Three meta-analyses17–19 and a systemic review20 have shown an identification rate of approximately 90% and a FNR of approximately 9%. In this study, 59 patients had positive SLNB but only 11 patients with positive SLNB underwent ANC (13.4% of patients who required ANC).
Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up
2021, European Journal of Surgical OncologyFuture perspectives of surgical treatment of breast cancer
2020, Annals of Medicine and SurgeryMagnetically guided surgery after primary systemic therapy for breast cancer: Implications for enhanced axillary mapping
2024, British Journal of Surgery